Sanofi 2Q: Dupixent's First Set Of Sales Are On Track
No surprises from Sanofi in the second quarter as sales of its flagship diabetes drug continue to fall – but a strong performance from recently launched Dupixent provided the French pharma with a refreshing reprieve in its earnings update.
